Papers
Topics
Authors
Recent
Gemini 2.5 Flash
Gemini 2.5 Flash
120 tokens/sec
GPT-4o
7 tokens/sec
Gemini 2.5 Pro Pro
46 tokens/sec
o3 Pro
4 tokens/sec
GPT-4.1 Pro
38 tokens/sec
DeepSeek R1 via Azure Pro
28 tokens/sec
2000 character limit reached

Integration of multiview microbiome data for deciphering microbiome-metabolome-disease pathways (2402.08222v2)

Published 13 Feb 2024 in stat.ME

Abstract: The intricate interplay between host organisms and their gut microbiota has catalyzed research into the microbiome's role in disease, shedding light on novel aspects of disease pathogenesis. However, the mechanisms through which the microbiome exerts its influence on disease remain largely unclear. In this study, we first introduce a structural equation model to delineate the pathways connecting the microbiome, metabolome, and disease processes, utilizing a target multiview microbiome data. To mitigate the challenges posed by hidden confounders, we further propose an integrative approach that incorporates data from an external microbiome cohort. This method also supports the identification of disease-specific and microbiome-associated metabolites that are missing in the target cohort. We provide theoretical underpinnings for the estimations derived from our integrative approach, demonstrating estimation consistency and asymptotic normality. The effectiveness of our methodologies is validated through comprehensive simulation studies and an empirical application to inflammatory bowel disease, highlighting their potential to unravel the complex relationships between the microbiome, metabolome, and disease.

Definition Search Book Streamline Icon: https://streamlinehq.com
References (41)
  1. Aitchison, J. (1982). The statistical analysis of compositional data. Journal of the Royal Statistical Society: Series B (Methodological), 44(2):139–160.
  2. Metabolomics insights into inflammatory bowel disease: a comprehensive review. Pharmaceuticals, 14(11):1190.
  3. Prediction-powered inference. arXiv preprint arXiv:2301.09633.
  4. Two-stage least squares estimation of average causal effects in models with variable treatment intensity. Journal of the American statistical Association, 90(430):431–442.
  5. Instrumental variable methods for causal inference. Statistics in medicine, 33(13):2297–2340.
  6. Simultaneous analysis of lasso and dantzig selector.
  7. Current understanding of dysbiosis in disease in human and animal models. Inflammatory bowel diseases, 22(5):1137–1150.
  8. 43 dietary fat-induced taurocholic acid production promotes pathobiont and colitis in il-10-/-mice. Gastroenterology, 142(5):S–12.
  9. Characterization of missing values in untargeted ms-based metabolomics data and evaluation of missing data handling strategies. Metabolomics, 14:1–18.
  10. Efron, B. (1994). Missing data, imputation, and the bootstrap. Journal of the American Statistical Association, 89(426):463–475.
  11. The role of the gut microbiota in nutrition and health. Nature reviews Gastroenterology & hepatology, 9(10):577–589.
  12. Gut microbiome structure and metabolic activity in inflammatory bowel disease. Nature microbiology, 4(2):293–305.
  13. A gene-based association method for mapping traits using reference transcriptome data. Nature genetics, 47(9):1091–1098.
  14. Rank-transformed subsampling: inference for multiple data splitting and exchangeable p-values. arXiv preprint arXiv:2301.02739.
  15. Confidence intervals for causal effects with invalid instruments by using two-stage hard thresholding with voting. Journal of the Royal Statistical Society Series B: Statistical Methodology, 80(4):793–815.
  16. Integrative approaches for large-scale transcriptome-wide association studies. Nature genetics, 48(3):245–252.
  17. Anti-inflammatory effects of maslinic acid, a natural triterpene, in cultured cortical astrocytes via suppression of nuclear factor-kappa b. European journal of pharmacology, 672(1-3):169–174.
  18. Kaakoush, N. O. (2015). Insights into the role of erysipelotrichaceae in the human host.
  19. Anti-inflammatory effects of urocanic acid derivatives in models ex vivo and in vivo of inflammatory bowel disease. International Scholarly Research Notices, 2012.
  20. Random forest-based imputation outperforms other methods for imputing lc-ms metabolomics data: a comparative study. BMC bioinformatics, 20(1):1–11.
  21. Fast gapped-read alignment with bowtie 2. Nature methods, 9(4):357–359.
  22. Regularization methods for high-dimensional instrumental variables regression with an application to genetical genomics. Journal of the American Statistical Association, 110(509):270–288.
  23. Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. Nature, 569(7758):655–662.
  24. Bracken: estimating species abundance in metagenomics data. PeerJ Computer Science, 3:e104.
  25. Emerging lysophospholipid mediators, lysophosphatidylserine, lysophosphatidylthreonine, lysophosphatidylethanolamine and lysophosphatidylglycerol. Prostaglandins & other lipid mediators, 89(3-4):135–139.
  26. Lysophosphatidylethanolamine in grifola frondosa as a neurotrophic activator via activation of mapk. Journal of lipid research, 47(7):1434–1443.
  27. A study of error variance estimation in lasso regression. Statistica Sinica, pages 35–67.
  28. α𝛼\alphaitalic_α-linolenic acid (ala) is an anti-inflammatory agent in inflammatory bowel disease. The Journal of Nutritional Biochemistry, 26(12):1632–1640.
  29. Asymmetric dimethylarginine and nitric oxide levels as signs of endothelial dysfunction in behcet’s disease. Annals of Clinical & Laboratory Science, 36(4):449–454.
  30. 4-hydroxybenzaldehyde sensitizes acinetobacter baumannii to amphenicols. Applied microbiology and biotechnology, 102:2323–2335.
  31. Fecal microbiota, fecal metabolome, and colorectal cancer interrelations. PloS one, 11(3):e0152126.
  32. Laboratory markers in ibd: useful, magic, or unnecessary toys? Gut, 55(3):426–431.
  33. Imputation of missing values for multi-biospecimen metabolomics studies: bias and effects on statistical validity. Metabolites, 12(7):671.
  34. Improved metagenomic analysis with kraken 2. Genome biology, 20:1–13.
  35. Transcriptome wide association studies: general framework and methods. Quantitative Biology, 9(2).
  36. Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer. Nature medicine, 25(6):968–976.
  37. Struo2: efficient metagenome profiling database construction for ever-expanding microbial genome datasets. PeerJ, 9:e12198.
  38. Mapping the genetic-imaging-clinical pathway with applications to alzheimer’s disease. Journal of the American Statistical Association, 117(540):1656–1668.
  39. Confidence intervals for low dimensional parameters in high dimensional linear models. Journal of the Royal Statistical Society: Series B: Statistical Methodology, pages 217–242.
  40. Testing in microbiome-profiling studies with mirkat, the microbiome regression-based kernel association test. The American Journal of Human Genetics, 96(5):797–807.
  41. Docosapentaenoic acid (dpa, 22: 5n-3) ameliorates inflammation in an ulcerative colitis model. Food & Function, 10(7):4199–4209.
Citations (1)

Summary

We haven't generated a summary for this paper yet.